Anika Therapeutics EBITDA Margin 2006-2021 | ANIK

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Anika Therapeutics (ANIK) over the last 10 years. The current EBITDA margin for Anika Therapeutics as of September 30, 2021 is .
Anika Therapeutics EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2021-09-30 $0.15B $0.04B 30.34%
2021-06-30 $0.14B $0.04B 26.28%
2021-03-31 $0.13B $0.02B 13.85%
2020-12-31 $0.13B $0.04B 31.30%
2020-09-30 $0.13B $0.03B 25.00%
2020-06-30 $0.13B $0.05B 37.30%
2020-03-31 $0.13B $0.06B 50.40%
2019-12-31 $0.12B $0.04B 34.78%
2019-09-30 $0.11B $0.04B 39.29%
2019-06-30 $0.11B $0.04B 37.61%
2019-03-31 $0.11B $0.04B 37.27%
2018-12-31 $0.11B $0.03B 26.42%
2018-09-30 $0.11B $0.03B 25.93%
2018-06-30 $0.11B $0.03B 26.85%
2018-03-31 $0.11B $0.04B 31.82%
2017-12-31 $0.11B $0.05B 44.64%
2017-09-30 $0.11B $0.05B 47.32%
2017-06-30 $0.11B $0.06B 51.35%
2017-03-31 $0.11B $0.05B 49.52%
2016-12-31 $0.10B $0.06B 52.88%
2016-09-30 $0.11B $0.06B 55.66%
2016-06-30 $0.10B $0.06B 55.77%
2016-03-31 $0.10B $0.06B 57.00%
2015-12-31 $0.09B $0.05B 54.26%
2015-09-30 $0.09B $0.05B 53.49%
2015-06-30 $0.08B $0.04B 51.19%
2015-03-31 $0.09B $0.05B 52.87%
2014-12-31 $0.11B $0.07B 61.90%
2014-09-30 $0.10B $0.06B 62.14%
2014-06-30 $0.10B $0.06B 62.63%
2014-03-31 $0.09B $0.06B 59.57%
2013-12-31 $0.08B $0.04B 49.33%
2013-09-30 $0.08B $0.03B 44.16%
2013-06-30 $0.07B $0.03B 39.19%
2013-03-31 $0.07B $0.03B 35.62%
2012-12-31 $0.07B $0.02B 33.33%
2012-09-30 $0.07B $0.02B 31.34%
2012-06-30 $0.07B $0.02B 32.86%
2012-03-31 $0.07B $0.02B 31.82%
2011-12-31 $0.06B $0.02B 28.13%
2011-09-30 $0.06B $0.02B 24.59%
2011-06-30 $0.06B $0.01B 21.05%
2011-03-31 $0.06B $0.01B 18.18%
2010-12-31 $0.06B $0.01B 20.00%
2010-09-30 $0.05B $0.01B 19.61%
2010-06-30 $0.05B $0.01B 18.75%
2010-03-31 $0.04B $0.01B 18.18%
2009-12-31 $0.04B $0.01B 17.07%
2009-09-30 $0.04B $0.01B 17.95%
2009-06-30 $0.04B $0.01B 18.92%
2009-03-31 $0.04B $0.01B 16.67%
2008-12-31 $0.04B $0.01B 16.67%
2008-09-30 $0.04B $0.01B 16.22%
2008-06-30 $0.04B $0.01B 16.67%
2008-03-31 $0.03B $0.01B 20.59%
2007-12-31 $0.03B $0.01B 22.58%
2007-09-30 $0.03B $0.01B 22.22%
2007-06-30 $0.03B $0.01B 24.00%
2007-03-31 $0.03B $0.01B 23.08%
2006-12-31 $0.03B $0.01B 22.22%
2006-09-30 $0.03B $0.01B 23.08%
2006-06-30 $0.03B $0.01B 26.67%
2006-03-31 $0.03B $0.01B 27.59%
2005-12-31 $0.03B $0.01B 31.03%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.570B $0.130B
Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95